BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20739883)

  • 1. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
    Brouwers MC; de Graaf J; van Greevenbroek MM; Schaper N; Stehouwer CD; Stalenhoef AF
    Curr Opin Lipidol; 2010 Dec; 21(6):530-8. PubMed ID: 20739883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
    Yki-Järvinen H
    Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
    den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
    Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of CD36/FAT in preadipocytes in familial combined hyperlipidemia.
    Meex SJ; van der Kallen CJ; van Greevenbroek MM; Eurlings PM; El Hasnaoui M; Evelo CT; Lindsey PJ; Luiken JJ; Glatz JF; de Bruin TW
    FASEB J; 2005 Dec; 19(14):2063-5. PubMed ID: 16219805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
    Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in the PPARgamma gene affect fatty acid and glycerol metabolism in familial combined hyperlipidemia.
    Eurlings PM; van der Kallen CJ; Vermeulen VM; de Bruin TW
    Mol Genet Metab; 2003 Nov; 80(3):296-301. PubMed ID: 14680975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year incidence of type 2 diabetes mellitus in patients with familial combined hyperlipidaemia.
    Brouwers MC; van der Kallen CJ; Schaper NC; van Greevenbroek MM; Stehouwer CD
    Neth J Med; 2010 Apr; 68(4):163-7. PubMed ID: 20421657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between familial combined hyperlipidemia and insulin resistance.
    Jackuliaková D; Vaverková H; Karásek D
    Vnitr Lek; 2008 Nov; 54(11):1045-53. PubMed ID: 19069677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    Ayyobi AF; Brunzell JD
    Am J Cardiol; 2003 Aug; 92(4A):27J-33J. PubMed ID: 12957324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 11. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic basis of obesity and type 2 diabetes: lessons from the new zealand obese mouse, a polygenic model of the metabolic syndrome.
    Joost HG
    Results Probl Cell Differ; 2010; 52():1-11. PubMed ID: 20865367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus.
    van der Kallen CJ; Voors-Pette C; Bouwman FG; Keizer HA; Lu JY; van de Hulst RR; Bianchi R; Janssen MJ; Keulen ET; Boeckx WD; Rotter JI; de Bruin TW
    Atherosclerosis; 2002 Oct; 164(2):337-46. PubMed ID: 12204806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial combined hyperlipidemia: upstream transcription factor 1 and beyond.
    Lee JC; Lusis AJ; Pajukanta P
    Curr Opin Lipidol; 2006 Apr; 17(2):101-9. PubMed ID: 16531745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1).
    Pajukanta P; Lilja HE; Sinsheimer JS; Cantor RM; Lusis AJ; Gentile M; Duan XJ; Soro-Paavonen A; Naukkarinen J; Saarela J; Laakso M; Ehnholm C; Taskinen MR; Peltonen L
    Nat Genet; 2004 Apr; 36(4):371-6. PubMed ID: 14991056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disorder of lipid metabolism in visceral fat syndrome--relation to familial combined hyperlipidemia].
    Ishigami M; Nakamura T; Matsuzawa Y
    Nihon Rinsho; 2002 May; 60(5):868-74. PubMed ID: 12029987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renaissance of metformin].
    Sieradzki J
    Przegl Lek; 1999; 56(5):331-4. PubMed ID: 10554568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
    Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome and nonalcoholic fatty liver disease.
    Collantes RS; Ong JP; Younossi ZM
    Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipose tissue dysfunction in obesity.
    Blüher M
    Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.